Corient Private Wealth
MRNA icon

Corient Private Wealth’s Moderna MRNA Stock Holding History

Corient Private Wealth’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.77M Sell
54,711
-48,350
-47% -$2.26M ﹤0.01% 1094
2025
Q4 		$3.04M Buy
103,061
+75,007
+267% +$2.04M ﹤0.01% 1302
2025
Q3 		$725K Sell
28,054
-28,346
-50% -$791K ﹤0.01% 1592
2025
Q2 		$1.54M Buy
56,400
+34,354
+156% +$905K ﹤0.01% 1160
2025
Q1 		$625K Buy
22,046
+3,508
+19% +$124K ﹤0.01% 1495
2024
Q4 		$771K Sell
18,538
-14,459
-44% -$691K ﹤0.01% 1430
2024
Q3 		$2.21M Buy
32,997
+2,604
+9% +$239K ﹤0.01% 1055
2024
Q2 		$3.61M Buy
30,393
+2,561
+9% +$324K 0.01% 806
2024
Q1 		$2.97M Buy
27,832
+4,150
+18% +$418K 0.01% 854
2023
Q4 		$2.36M Buy
23,682
+2,855
+14% +$240K ﹤0.01% 931
2023
Q3 		$2.15M Sell
20,827
-3,597
-15% -$401K 0.01% 883
2023
Q2 		$2.97M Sell
24,424
-9,416
-28% -$1.26M 0.01% 780
2023
Q1 		$5.2M Sell
33,840
-1,185
-3% -$195K 0.01% 584
2022
Q4 		$6.29M Buy
+35,025
New +$5.73M 0.02% 443

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Corient Private Wealth's MRNA Position: Q1 2026 in Review

Corient Private Wealth reduced its Moderna (MRNA) stake by 47% in Q1 2026, selling an estimated $2.26M and leaving 54,711 shares worth $2.77M. The position accounts for ﹤0.01% of the portfolio, ranked #1094.

Corient Private Wealth first reported a position in MRNA in Q4 2022 and has held it in 14 quarters since. The position peaked at $6.29M in Q4 2022. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Corient Private Wealth held 54,711 shares of Moderna worth $2.77M as of Q1 2026.
  • Corient Private Wealth sold 48,350 Moderna shares in Q1 2026, an estimated $2.26M.
  • Moderna made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #1094 holding.
  • Corient Private Wealth first reported a position in Moderna in Q4 2022 and has held it in 14 quarters since.
  • Corient Private Wealth's Moderna position peaked at $6.29M in Q4 2022.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.